Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-specific neoantigen peptide-HLA complexes represent a highly personalized class of therapeutic targets on melanoma and other cancer cells. These complexes are formed when somatic mutations unique to a patient's tumor (neoantigens) are processed intracellularly and presented on the cell surface by human leukocyte antigen (HLA) molecules. Because these neoantigens are entirely absent from normal tissues, targeting these complexes minimizes the risk of on-target, off-tumor toxicities, making them ideal candidates for precision immunotherapy.
Therapeutic strategies targeting these complexes include individualized cancer vaccines (such as mRNA-4157/V940 and autogene cevumeran/BNT122) that train the patient's immune system to recognize these specific peptide-HLA presentations. Additionally, adoptive cell therapies, such as NeoTCR-P1, utilize CRISPR-engineered autologous T cells expressing T-cell receptors (TCRs) specifically cloned to bind these patient-specific neoantigen-HLA complexes. Clinical trials in melanoma have demonstrated that targeting these complexes can induce robust, durable de novo T-cell responses, leading to significant improvements in recurrence-free and distant metastasis-free survival when combined with immune checkpoint inhibitors.
Individualized neoantigen therapies (such as mRNA vaccines) encode patient-specific tumor neoantigens that are translated and presented as peptide-HLA complexes to stimulate endogenous T-cell responses, while adoptive TCR-T therapies utilize engineered T cells expressing TCRs that directly bind and destroy cells presenting these complexes.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-specific neoantigen peptide-HLA complexes (neoantigen-HLA).